FindTrial
Sign In

Establishment of bleeding risk score model of low molecular weight heparin in prevention and treatment of venous thromboembolism in tumor patients

Bleeding risk scoring model of low molecular weight heparin in the prevention and treatment of venous thromboembolism in cancer patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066064
Enrollment
Unknown
Registered
2022-11-23
Start date
2022-11-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism

Interventions

Bleeding group:N/A
Non bleeding group:N/A

Sponsors

Ziyang First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Age =18 years; (2) Low molecular weight heparin was used to prevent and treat VTE. (3) Hospitalized patients diagnosed with tumor

Exclusion criteria

Exclusion criteria: Patients who did not receive low molecular weight heparin

Design outcomes

Primary

MeasureTime frame
Bleeding rate;—

Countries

China

Contacts

Public Contactzhangziyu

Ziyang First People's Hospital

842940641@qq.com13568539636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026